PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
14534356-1	2003	The apparent inhibition constant, Kapp, for the blockade of P-glycoprotein (P-gp) by four drugs, verapamil, cyclosporin A, XR9576 (tariquidar), and vinblastine, was measured by studying their ability to inhibit daunorubicin and calcein-AM efflux from four strains of Ehrlich cells with different levels of drug resistance and P-gp content.	calcein AM	228-238	phosphoglycolate phosphatase	Mus musculus	60-74
12948014-1	2003	PURPOSE: The purpose of this study was to establish a fluorescent dye (calcein-acetoxymethylester; calcein-AM)-based assay to rapidly screen compounds for interactions with p-glycoprotein (p-gp) at the blood-brain barrier and to determine whether such an assay can be useful for kinetic analysis.	calcein AM	99-109	ATP binding cassette subfamily B member 1	Homo sapiens	173-187
12909621-5	2003	TMEA is a cross-linker substrate of P-gp that allowed us to test for stimulation of cross-linking by a second substrate such as calcein-acetoxymethyl ester, colchicine, demecolcine, cyclosporin A, rhodamine B, progesterone, and verapamil.	calcein AM	128-155	phosphoglycolate phosphatase	Homo sapiens	36-40
12975485-7	2003	The Ki values for the inhibition of P-gp function by cyclosporin A and imatinib mesilate were estimated to be 6.1 and 18.3 muM, respectively, using a calcein-AM efflux assay.	calcein AM	150-160	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
12948014-1	2003	PURPOSE: The purpose of this study was to establish a fluorescent dye (calcein-acetoxymethylester; calcein-AM)-based assay to rapidly screen compounds for interactions with p-glycoprotein (p-gp) at the blood-brain barrier and to determine whether such an assay can be useful for kinetic analysis.	calcein AM	99-109	ATP binding cassette subfamily B member 1	Homo sapiens	189-193
12948014-4	2003	RESULTS: PBCECs showed stable expression of p-gp and as a result calcein-AM was extruded by the cells.	calcein AM	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
12948014-5	2003	In the presence of p-gp substrates and inhibitors a significant increase of intracellular fluorescence was observed (decreased calcein-AM efflux), the increase being well correlated with the p-gp affinity of the compounds used.	calcein AM	127-137	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
12948014-5	2003	In the presence of p-gp substrates and inhibitors a significant increase of intracellular fluorescence was observed (decreased calcein-AM efflux), the increase being well correlated with the p-gp affinity of the compounds used.	calcein AM	127-137	ATP binding cassette subfamily B member 1	Homo sapiens	191-195
12948014-8	2003	CONCLUSION: The calcein-AM-assay based on PBCECs can be used as a rapid microplate screening system for interactions of drugs with p-glycoprotein at the blood-brain barrier and represents therefore a useful tool in the profiling of drugs.	calcein AM	16-26	ATP binding cassette subfamily B member 1	Homo sapiens	131-145
12614568-3	2003	The ability to confer drug resistance by three ABC transporter genes (MDR 1, MRP 1, or MXR) was determined using the surrogate fluorescent substrates rhodamine-123 or calcein AM and their specific inhibitors, or by using specific antibodies to the transporters to detect cell surface expression by fluorescence-activated cell sorter analysis (FACS).	calcein AM	167-177	ATP binding cassette subfamily B member 1	Homo sapiens	70-75
12614568-3	2003	The ability to confer drug resistance by three ABC transporter genes (MDR 1, MRP 1, or MXR) was determined using the surrogate fluorescent substrates rhodamine-123 or calcein AM and their specific inhibitors, or by using specific antibodies to the transporters to detect cell surface expression by fluorescence-activated cell sorter analysis (FACS).	calcein AM	167-177	ATP binding cassette subfamily C member 1	Homo sapiens	77-82
12614568-3	2003	The ability to confer drug resistance by three ABC transporter genes (MDR 1, MRP 1, or MXR) was determined using the surrogate fluorescent substrates rhodamine-123 or calcein AM and their specific inhibitors, or by using specific antibodies to the transporters to detect cell surface expression by fluorescence-activated cell sorter analysis (FACS).	calcein AM	167-177	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	87-90
12421806-9	2003	Substrates that stimulated the ATPase activity of P-gp (calcein-AM, demecolcine, cis(Z)-flupentixol, and verapamil) increased the rate of cross-linking between Cys(431)(NBD1-Walker A)/C1176C(NBD2-LSGGQ) and between Cys(1074)(NBD2-Walker A)/L531C(NBD1-LSGGQ) when compared with cross-linking in the absence of drug substrate.	calcein AM	56-66	phosphoglycolate phosphatase	Homo sapiens	50-54
12235267-5	2002	Pgp antagonism was defined by interactions of the drugs with four cell lines (LLC-PK1, L-MDR1, L-mdr1a, and L-mdr1b) using a microfluorometric calcein-AM assay and characterized for their inhibitor constant (K(i)) toward calcein-AM.	calcein AM	143-153	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
12454976-4	2002	P-glycoprotein and multidrug-resistant protein (MRP)-mediated efflux were quantitated using fluorescent substrates (rhodamine-123 and calcein acetoxymethyl ester [calcein-AM]) and specific inhibitors (verapamil and probenecid, respectively).	calcein AM	134-161	ATP binding cassette subfamily C member 1	Homo sapiens	48-51
12454976-4	2002	P-glycoprotein and multidrug-resistant protein (MRP)-mediated efflux were quantitated using fluorescent substrates (rhodamine-123 and calcein acetoxymethyl ester [calcein-AM]) and specific inhibitors (verapamil and probenecid, respectively).	calcein AM	163-173	ATP binding cassette subfamily C member 1	Homo sapiens	48-51
12488494-5	2002	Preincubation of in vitro C-AM-labeled leukocytes with anti-CD44 monoclonal antibodies (mAb; IM7) or high molecular weight hyaluronic acid (HA) before transfer significantly suppressed leukocyte rolling but not sticking in retinal venules and also reduced cell infiltration in the retinal parenchyma.	calcein AM	26-30	CD44 antigen	Mus musculus	60-64
12235267-5	2002	Pgp antagonism was defined by interactions of the drugs with four cell lines (LLC-PK1, L-MDR1, L-mdr1a, and L-mdr1b) using a microfluorometric calcein-AM assay and characterized for their inhibitor constant (K(i)) toward calcein-AM.	calcein AM	221-231	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
11856485-4	2002	The K(i) values for P-gp of cyclosporine and verapamil were 1.09 and 540 microM, respectively, and that of bromocriptine was 6.52 microM in a calcein-AM efflux assay using porcine kidney epithelial LLC-PK1 and L-MDR1 cells, overexpressing human P-gp.	calcein AM	142-152	phosphoglycolate phosphatase	Homo sapiens	20-24
11856485-4	2002	The K(i) values for P-gp of cyclosporine and verapamil were 1.09 and 540 microM, respectively, and that of bromocriptine was 6.52 microM in a calcein-AM efflux assay using porcine kidney epithelial LLC-PK1 and L-MDR1 cells, overexpressing human P-gp.	calcein AM	142-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	212-216
11856485-4	2002	The K(i) values for P-gp of cyclosporine and verapamil were 1.09 and 540 microM, respectively, and that of bromocriptine was 6.52 microM in a calcein-AM efflux assay using porcine kidney epithelial LLC-PK1 and L-MDR1 cells, overexpressing human P-gp.	calcein AM	142-152	phosphoglycolate phosphatase	Homo sapiens	245-249
11602674-10	2001	The calcein-AM and ATPase assays revealed Pgp interactions for highly permeable group IIA compounds but were less responsive than monolayer efflux for low/moderate P(app) compounds of group IIB.	calcein AM	4-14	ATP binding cassette subfamily B member 1	Homo sapiens	42-45
11587213-4	2001	A fluorescent probe assay using Syto16/PSC833 and calcein-AM/probenecid as substrate/modulator of the Pgp and MRP pump, respectively, and subsequent labeling of cells with monoclonal antibodies for LAP detection allowed simultaneous detection of LAP and Pgp or MRP activity.	calcein AM	50-60	ATP binding cassette subfamily C member 1	Homo sapiens	110-113
11288109-3	2001	In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol.	calcein AM	78-105	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
11288109-3	2001	In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol.	calcein AM	78-105	ATP binding cassette subfamily B member 1	Homo sapiens	165-168
11288109-3	2001	In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol.	calcein AM	107-117	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
11288109-3	2001	In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol.	calcein AM	107-117	ATP binding cassette subfamily B member 1	Homo sapiens	165-168
11309820-8	2001	We conclude that calcein AM, when used in a retention assay with MRP1-specific modulators, is able to reliably detect MRP functional activity.	calcein AM	17-27	ATP binding cassette subfamily C member 1	Homo sapiens	65-69
11309820-8	2001	We conclude that calcein AM, when used in a retention assay with MRP1-specific modulators, is able to reliably detect MRP functional activity.	calcein AM	17-27	ATP binding cassette subfamily C member 1	Homo sapiens	65-68
10997969-4	2000	The efflux test using calcein-AM (CAM) +/- probenecid to evaluate MRP1 activity was performed in ten of the 56 patients.	calcein AM	22-32	calmodulin 3	Homo sapiens	34-37
10617675-9	2000	However, further studies demonstrated that, like MDR1, SPGP effluxed calcein-acetoxymethyl ester (AM).	calcein AM	69-96	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	55-59
10917553-8	2000	Unexpectedly, export of the organic anion calcein by MDCKII-MRP1 and MDCKII-MRP2 cells is stimulated by Pluronic L61, probably because it relieves the block on entry of calcein AM into the cell by endogenous MDR1 Pgp.	calcein AM	169-179	ATP binding cassette subfamily C member 2	Canis lupus familiaris	76-80
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	calcein AM	85-95	phosphoglycolate phosphatase	Homo sapiens	38-41
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	calcein AM	85-95	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	calcein AM	85-95	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	calcein AM	85-95	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	calcein AM	85-95	phosphoglycolate phosphatase	Homo sapiens	58-61
10817732-1	2000	To investigate interactions between the multidrug resistance protein (MRP) and antimicrobial agents, we examined the effects of 12 agents on vincristine sensitivity and efflux of the calcein acetoxy-methyl ester (calcein-AM) of a MRP substrate in MRP-overexpressing cells.	calcein AM	183-211	ATP binding cassette subfamily C member 1	Homo sapiens	70-73
10817732-1	2000	To investigate interactions between the multidrug resistance protein (MRP) and antimicrobial agents, we examined the effects of 12 agents on vincristine sensitivity and efflux of the calcein acetoxy-methyl ester (calcein-AM) of a MRP substrate in MRP-overexpressing cells.	calcein AM	183-211	ATP binding cassette subfamily C member 1	Homo sapiens	230-233
10817732-1	2000	To investigate interactions between the multidrug resistance protein (MRP) and antimicrobial agents, we examined the effects of 12 agents on vincristine sensitivity and efflux of the calcein acetoxy-methyl ester (calcein-AM) of a MRP substrate in MRP-overexpressing cells.	calcein AM	183-211	ATP binding cassette subfamily C member 1	Homo sapiens	230-233
10617675-9	2000	However, further studies demonstrated that, like MDR1, SPGP effluxed calcein-acetoxymethyl ester (AM).	calcein AM	69-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-53
10838122-3	2000	Results showed that the accumulation of P-gp substrates calcein-AM and vinblastine by BeWo cells or primary cultures of human cytotrophoblasts was significantly enhanced in the presence of a typical P-gp inhibitor, cyclosporin-A, or other inhibitors such as quinidine, verapamil, and dipyridamole.	calcein AM	56-66	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
10838122-3	2000	Results showed that the accumulation of P-gp substrates calcein-AM and vinblastine by BeWo cells or primary cultures of human cytotrophoblasts was significantly enhanced in the presence of a typical P-gp inhibitor, cyclosporin-A, or other inhibitors such as quinidine, verapamil, and dipyridamole.	calcein AM	56-66	ATP binding cassette subfamily B member 1	Homo sapiens	199-203
10729360-11	2000	PAK-104P also non-competitively inhibits the MRP(1)-mediated efflux of daunorubicin, pirarubicin, hydroxyrubicin, calcein acetoxymethyl ester and calcein.	calcein AM	114-141	ATP binding cassette subfamily C member 1	Homo sapiens	45-50
10617675-11	2000	Although cyclosporine A and reserpine blocked calcein-AM transport by MDR1, these drugs had either minimal or no effect, respectively, on blocking SPGP efflux of calcein-AM.	calcein AM	46-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	70-74
10617675-12	2000	In contrast, ditekiren, a linear hexapeptide, readily and preferentially inhibited SPGP efflux of calcein-AM.	calcein AM	98-108	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	83-87
10617675-13	2000	Further studies with three structural analogs of ditekiren revealed that one analog inhibited SPGP efflux of calcein-AM, although not as potently as ditekiren.	calcein AM	109-119	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	94-98
10635304-4	1999	Using flow cytometry and confocal laser scan microscopy, MC540 and calcein-AM were bound intracellularly and effluxed by P-gp in K562/ADM.	calcein AM	67-77	ATP binding cassette subfamily B member 1	Homo sapiens	121-125
10635304-5	1999	In K562/ADM, calcein-AM efflux was inhibited by P-gp modulator, cyclosporin A (5 microM) and verapamil (15 micrograms/ml).	calcein AM	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
10628392-6	1999	P-gp extrudes calcein-AM directly from the cell membrane, but not calcein.	calcein AM	14-24	phosphoglycolate phosphatase	Mus musculus	0-4
10413294-8	1999	Reversin 121 and reversin 205 restored the uptake of [3H]daunorubicin and rhodamine 123 in MDR1-expressing cells to the level observed in the drug-sensitive parent cell lines, and also effectively inhibited the extrusion of calcein acetoxymethyl ester from intact cells.	calcein AM	224-251	ATP binding cassette subfamily B member 1	Homo sapiens	91-95
10419897-4	1999	However, a strong correlation was observed between the simultaneous activity of MRP1 and Pgp (quantified as the modulation of calcein-AM uptake by cyclosporin A and probenecid) and the LC50 of DNR (r =.77, P <.0001).	calcein AM	126-136	ATP binding cassette subfamily C member 1	Homo sapiens	80-84
10500791-2	1999	There was a good correlation between MRP1 expression and the modulatory effect of probenecid (a specific modulator of MRP1) on the calcein efflux (r = 0.91, p = 0.0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r = 0.96, p < 0.0001).	calcein AM	232-242	CD9 molecule	Homo sapiens	37-41
10198227-3	1999	The initial rates (in percent) for calcein retention by these MDR-1 cells were used to calculate values for the percent initial efflux of calcein-AM through the MDR pump in the presence of the inhibitors PSC833, cyclosporinA, and dexniguldipine.	calcein AM	138-148	ATP binding cassette subfamily B member 1	Homo sapiens	62-67
10419897-4	1999	However, a strong correlation was observed between the simultaneous activity of MRP1 and Pgp (quantified as the modulation of calcein-AM uptake by cyclosporin A and probenecid) and the LC50 of DNR (r =.77, P <.0001).	calcein AM	126-136	phosphoglycolate phosphatase	Homo sapiens	89-92
10500791-0	1999	Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.	calcein AM	35-45	phosphoglycolate phosphatase	Homo sapiens	5-8
10500791-2	1999	There was a good correlation between MRP1 expression and the modulatory effect of probenecid (a specific modulator of MRP1) on the calcein efflux (r = 0.91, p = 0.0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r = 0.96, p < 0.0001).	calcein AM	232-242	CD9 molecule	Homo sapiens	118-122
10500791-0	1999	Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.	calcein AM	35-45	CD9 molecule	Homo sapiens	13-17
10500791-4	1999	In 53 AML patients, there was also a good correlation between MRP1 expression (measured by RT/PCR and by MRPm6 expression by flow cytometry) and the modulatory effect of probenecid on the calcein fluorescence (r = 0.92, p < 0.0001) and between Pgp expression as measured by UIC2 antibody binding on flow cytometry and the modulatory effect of CsA on calcein-AM uptake (r = 0.83, p < 0.0001).	calcein AM	353-363	CD9 molecule	Homo sapiens	62-66
10500791-8	1999	These results suggest that functional testing (with calcein-AM +/- modulators) for the presence of both MRP1 and Pgp activities is of prognostic value and that MRP1 contributes to drug resistance in AML.	calcein AM	52-62	CD9 molecule	Homo sapiens	104-108
10500791-8	1999	These results suggest that functional testing (with calcein-AM +/- modulators) for the presence of both MRP1 and Pgp activities is of prognostic value and that MRP1 contributes to drug resistance in AML.	calcein AM	52-62	phosphoglycolate phosphatase	Homo sapiens	113-116
9835508-2	1998	Calcein fluorescence was significantly enhanced in MDR1(+) CEM/VBL100 and MRP1(+) CEM/VM-1-5 cells incubated in the presence of various HIV PIs and calcein acetoxymethyl ester.	calcein AM	148-175	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
9835508-2	1998	Calcein fluorescence was significantly enhanced in MDR1(+) CEM/VBL100 and MRP1(+) CEM/VM-1-5 cells incubated in the presence of various HIV PIs and calcein acetoxymethyl ester.	calcein AM	148-175	ATP binding cassette subfamily C member 1	Homo sapiens	74-78
9616142-2	1998	There was a good correlation between MRP expression and the modulatory effect of probenecid (a specific modulator of MRP) on the calcein efflux (r = .91, P = .0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r = .96, P < .0001).	calcein AM	228-238	MARCKS like 1	Homo sapiens	37-40
9616142-8	1998	These results suggest that functional testing (with calcein-AM +/- modulators) for the presence of both MRP and Pgp activities is of prognostic value and that MRP contributes to drug resistance in AML.	calcein AM	52-62	MARCKS like 1	Homo sapiens	104-107
9616142-0	1998	Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.	calcein AM	29-39	phosphoglycolate phosphatase	Homo sapiens	0-3
9616142-8	1998	These results suggest that functional testing (with calcein-AM +/- modulators) for the presence of both MRP and Pgp activities is of prognostic value and that MRP contributes to drug resistance in AML.	calcein AM	52-62	phosphoglycolate phosphatase	Homo sapiens	112-115
9616142-0	1998	Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.	calcein AM	29-39	MARCKS like 1	Homo sapiens	8-11
9485370-3	1998	To obtain more insight in the handling of drugs by both proteins, we performed a detailed kinetic analysis of the efflux of calcein-acetoxymethyl ester (CAL-AM), a common neutral substrate for both proteins and compared it with the kinetics of efflux of calcein (CAL) which is only effluxed by MRP.	calcein AM	124-151	ATP binding cassette subfamily C member 1	Homo sapiens	294-297
9485370-7	1998	The results showed that the Vmax for efflux of CAL-AM and CAL by MRP were very similar (1.0-1.2 x 10(5) molecules/cell/s) but that the Km for CAL-AM was much lower (0.05 microM) than for CAL (268 microM).	calcein AM	47-53	ATP binding cassette subfamily C member 1	Homo sapiens	65-68
9485370-3	1998	To obtain more insight in the handling of drugs by both proteins, we performed a detailed kinetic analysis of the efflux of calcein-acetoxymethyl ester (CAL-AM), a common neutral substrate for both proteins and compared it with the kinetics of efflux of calcein (CAL) which is only effluxed by MRP.	calcein AM	153-159	ATP binding cassette subfamily C member 1	Homo sapiens	294-297
9485370-7	1998	The results showed that the Vmax for efflux of CAL-AM and CAL by MRP were very similar (1.0-1.2 x 10(5) molecules/cell/s) but that the Km for CAL-AM was much lower (0.05 microM) than for CAL (268 microM).	calcein AM	142-148	ATP binding cassette subfamily C member 1	Homo sapiens	65-68
9287320-6	1997	For some other drugs (e.g. valinomycin or calcein acetoxymethylester) activation of the MDR1-ATPase for any of the mutants was indistinguishable from that of the wild-type protein.	calcein AM	42-68	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
9485370-9	1998	The Km for CAL-AM transport by Pgp (0.12 microM) was similar to that for MRP.	calcein AM	11-17	ATP binding cassette subfamily B member 1	Homo sapiens	31-34
9485370-10	1998	Compared to previously published data for anthracyclines, the kinetic data for MRP-mediated CAL-AM pumping are most similar to those for the neutral hydroxydaunorubicin.	calcein AM	92-98	ATP binding cassette subfamily C member 1	Homo sapiens	79-82
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	calcein AM	203-230	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	calcein AM	203-230	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	calcein AM	232-238	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	calcein AM	232-238	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
9353133-5	1997	Accumulation of the P-gp substrate Cal-AM was not influenced by PMA in wild-type cells.	calcein AM	35-41	ATP binding cassette subfamily B member 1	Homo sapiens	20-24
9353133-6	1997	Therefore, Cal-AM was used to study the effect of PMA-induced phosphorylation of P-gp on its transport activity.	calcein AM	11-17	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
9287320-6	1997	For some other drugs (e.g. valinomycin or calcein acetoxymethylester) activation of the MDR1-ATPase for any of the mutants was indistinguishable from that of the wild-type protein.	calcein AM	42-68	dynein axonemal heavy chain 8	Homo sapiens	93-99
8611394-5	1996	The transport function of the P-gp was assessed by measuring the extrusion of calcein acetoxymethyl ester (AM) with fluorometry and flow cytometry, while in parallel experiments drug resistance was directly examined in cell survival assays.	calcein AM	78-105	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
8862725-2	1996	The model assay measures the capacity of parental sensitive (Par) and multidrug-resistant (MDR) cells to efflux a small fixed amount of acetoxymethyl calcein (calcein-AM) after their pretreatment with concentration ranges of known Pgp modulators.	calcein AM	159-169	ATP binding cassette subfamily B member 1	Homo sapiens	231-234
7909692-7	1994	Since calcein-AM is not fluorescent and free calcein is not a substrate of the multidrug transporter, the assay is readily applicable for rapid kinetic studies of the MDR1 function.	calcein AM	6-16	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
7669559-6	1995	In contrast to R123, a 60 min DNR or calcein-AM accumulation test could be used to detect MRP-mediated resistance.	calcein AM	37-47	ATP binding cassette subfamily C member 3	Homo sapiens	90-93
7628644-1	1995	In this study we report that the multidrug resistance protein (MRP) transports calcein from the cytoplasmic compartment of tumor cells, in contrast to P-glycoprotein which transports calcein acetoxymethyl ester from the plasmamembrane.	calcein AM	183-210	ATP binding cassette subfamily C member 1	Homo sapiens	63-66
7790401-1	1995	A new pH indicator, seminaphthofluorescein (SNAFL)-calcein acetoxymethyl ester, was used for intracellular pH (pHi) measurement in living MDCK cells with a laser scanning confocal microscope (LSCM) equipped with an Argon/Krypton laser and dual-excitation and dual-emission (FITC/Texas Red) filter set.	calcein AM	51-78	glucose-6-phosphate isomerase	Homo sapiens	111-114
7910563-0	1994	Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833.	calcein AM	32-59	ATP binding cassette subfamily B member 1	Homo sapiens	75-89
8354887-8	1993	To monitor the reliability and reproducibility of this method, we followed the adherence of Calcein AM-labeled THP-1 cells, a human monocytic cell line, to human endothelial cells treated with interleukin-1.	calcein AM	92-102	interleukin 1 alpha	Homo sapiens	193-206
34954996-6	2021	The cell efflux test was used to detect the effect of up-regulated USP22 on Calcein-AM and rhodamine123.	calcein AM	76-86	ubiquitin specific peptidase 22	Homo sapiens	67-72
35327403-11	2022	Moreover, the efflux of Calcein AM, a well-known substrate for ABCB1, was also significantly impaired in BGJ 398-treated cancer cells, thereby suggesting the ABCB1 as a novel molecular target for BGJ 398.	calcein AM	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	63-68
35327403-11	2022	Moreover, the efflux of Calcein AM, a well-known substrate for ABCB1, was also significantly impaired in BGJ 398-treated cancer cells, thereby suggesting the ABCB1 as a novel molecular target for BGJ 398.	calcein AM	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	158-163
35162941-8	2022	This was accompanied by increased transport activity, as shown by export of the P-gp substrate calcein-AM, as well as enhanced secretion of Abeta peptides, as shown by ELISA.	calcein AM	95-105	ATP binding cassette subfamily B member 1	Homo sapiens	80-84
35262277-6	2022	Furthermore, NRVMs grown on stiff (~GPa), flat or microgrooved substrates coated with TTR fibrils exhibited significantly decreased intercellular electrical coupling as shown by FRAP dynamics of cells loaded with the gap junction-permeable dye calcein-AM, along with decreased gap junction content as determined by quantitative connexin 43 staining.	calcein AM	244-254	transthyretin	Mus musculus	86-89
31290055-7	2019	Upon uptake, PTEN-nanocomposites led to modulation of cyclins and apoptosis gene regulators culminating in cell cycle arrest and reduced cell viability as confirmed by calcein-AM/PI dual staining and alamar blue assay.	calcein AM	168-178	phosphatase and tensin homolog	Homo sapiens	13-17
33735724-4	2021	METHODS: Calcein-AM, rhodamine 123, and doxorubicin were fluorescent substrates for the evaluation of P-gp inhibitory function and detailed drug binding modes.	calcein AM	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
30353640-5	2019	In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment.	calcein AM	48-58	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
30353640-5	2019	In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment.	calcein AM	48-58	CD9 molecule	Homo sapiens	72-76
30353640-5	2019	In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment.	calcein AM	48-58	BCR pseudogene 1	Homo sapiens	98-102
30353640-5	2019	In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment.	calcein AM	48-58	ATP binding cassette subfamily B member 1	Homo sapiens	253-257
30353640-5	2019	In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment.	calcein AM	48-58	CD9 molecule	Homo sapiens	262-266
30353640-5	2019	In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment.	calcein AM	48-58	CD9 molecule	Homo sapiens	262-266
30353640-5	2019	In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment.	calcein AM	48-58	BCR pseudogene 1	Homo sapiens	304-308
32633057-6	2020	Results from Calcein-AM/PI staining and Ki67 immunofluorescence tests demonstrated that the survival and proliferation behavior of hUC-MSCs were highly enhanced in HRP1U ChOx0.25U hydrogel with lower modulus and less H2 O2 release compared with other groups.	calcein AM	13-23	ubiquitin specific peptidase 6	Homo sapiens	164-168
32626923-6	2020	Cell Counting Kit-8 assays, Hoechst staining, calcein-AM/PI staining, immunostaining, water maze tests and rotarod tests demonstrated that BDNF-AS silencing protected against hypoxia-induced primary hippocampal neuron injury in vitro and HI-induced brain injury in vivo.	calcein AM	46-56	BDNF antisense RNA	Homo sapiens	139-146
32097312-4	2020	The histologic structure and viability of the prepared fat samples were evaluated by calcein AM/propidium iodide staining.	calcein AM	85-95	FAT atypical cadherin 1	Homo sapiens	55-58
31639417-8	2019	Microdevices were shown to inhibit P-gp mediated transport of calcein AM, doxorubicin, and rhodamine 123 (R123) and BCRP mediated transport of BODIPY-FL-prazosin.	calcein AM	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
31581572-7	2019	Intracellular doxorubicin accumulation and transported calcein acetoxymethyl (AM) (a substrate for p-glycoprotein) were both increased when cancer cells with MDR were treated with compound 160a.	calcein AM	55-76	ATP binding cassette subfamily B member 1	Homo sapiens	99-113
30414939-9	2019	MCF-7 Tet-Off/ACSL4 cells showed greater doxorubicin, Hoechst 33342 and calcein AM efflux.	calcein AM	72-82	acyl-CoA synthetase long chain family member 4	Homo sapiens	14-19
31538529-2	2019	Results & methodology: Most of the synthesized compounds were selective P-gp inhibitors in Calcein-AM uptake assay.	calcein AM	95-105	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
30925062-3	2019	The best hit molecule-a thienopyrimidine-was a moderately potent, competitive inhibitor of the ABCC1-mediated transport of calcein AM which also sensitized ABCC1-overexpressing cells toward daunorubicin.	calcein AM	123-133	ATP binding cassette subfamily C member 1	Homo sapiens	95-100
30925062-3	2019	The best hit molecule-a thienopyrimidine-was a moderately potent, competitive inhibitor of the ABCC1-mediated transport of calcein AM which also sensitized ABCC1-overexpressing cells toward daunorubicin.	calcein AM	123-133	ATP binding cassette subfamily C member 1	Homo sapiens	156-161
30925062-4	2019	Further evaluation showed that it was a moderately potent, competitive inhibitor of the ABCB1-mediated transport of calcein AM, and noncompetitive inhibitor of the ABCG2-mediated pheophorbide A transport.	calcein AM	116-126	ATP binding cassette subfamily B member 1	Homo sapiens	88-93
30594677-9	2019	The synthesized molecules were evaluated for their inhibitory potential against ABCB1, ABCC1, and ABCG2 in calcein AM and pheophorbide A assays.	calcein AM	107-117	ATP binding cassette subfamily B member 1	Homo sapiens	80-85
30594677-9	2019	The synthesized molecules were evaluated for their inhibitory potential against ABCB1, ABCC1, and ABCG2 in calcein AM and pheophorbide A assays.	calcein AM	107-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	98-103
30252954-9	2018	Moreover, cell volume measurements using calcein-AM dye further revealed that LRRC8A also substantially contributes to RVD.	calcein AM	41-51	leucine rich repeat containing 8 VRAC subunit A	Homo sapiens	78-84
30469543-5	2018	The transporter inhibition ability was evaluated in human P-gp stable expression cells (ABCB1/Flp-InTM-293) by calcein-AM uptake assays.	calcein AM	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
30469543-5	2018	The transporter inhibition ability was evaluated in human P-gp stable expression cells (ABCB1/Flp-InTM-293) by calcein-AM uptake assays.	calcein AM	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	88-93
30466981-16	2018	Furthermore, Rhodamine 123 and Calcein-AM were used to detect the effects of polyphenols on the activity of P-gp.	calcein AM	31-41	phosphoglycolate phosphatase	Homo sapiens	108-112
29854771-5	2018	Further, the viability of PC3 cells in 3D matrix was suppressed by C12-HSL treatment as detected using calcein AM fluorescence in situ.	calcein AM	103-113	lipase E, hormone sensitive type	Homo sapiens	71-74
30051196-7	2018	Functionality of the efflux transporters P-gp and MRP2/4 was studied as proof-of-concept for 3D assays using calcein-AM and 5-chloromethylfluorescein-diacetate (CMFDA), respectively.	calcein AM	109-119	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
30051196-7	2018	Functionality of the efflux transporters P-gp and MRP2/4 was studied as proof-of-concept for 3D assays using calcein-AM and 5-chloromethylfluorescein-diacetate (CMFDA), respectively.	calcein AM	109-119	ATP binding cassette subfamily C member 2	Homo sapiens	50-56
28912036-6	2017	Indeed, ZSTK474 increased the cellular accumulation of calcein-AM and mitoxantrone in cells expressing ABCB1 and ABCG2, respectively.	calcein AM	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	103-108
30023810-4	2018	Honokiol, magnolol, CAPE, xanthohumol, and anacardic acid activated the MDR1 promoter in LS174T cells, and the cellular uptake of rhodamine 123 and calcein-AM, fluorescent substrates of P-glycoprotein, decreased in polyphenol-treated LS174T cells.	calcein AM	148-158	ATP binding cassette subfamily B member 1	Homo sapiens	186-200
28912036-6	2017	Indeed, ZSTK474 increased the cellular accumulation of calcein-AM and mitoxantrone in cells expressing ABCB1 and ABCG2, respectively.	calcein AM	55-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	113-118
28899501-10	2017	The P-gp functional studies showed that these three alkaloids increased the accumulation of P-gp substrates, calcein-AM (C-AM) and rhodamine123 (Rho 123) in K562/Adr cells, while this effect was not seen in drug sensitive parental K562 cells.	calcein AM	109-119	phosphoglycolate phosphatase	Homo sapiens	4-8
29016119-6	2017	Additionally, the compound is a noncompetitive inhibitor of daunorubicin (MRP1), calcein AM (P-gp), and pheophorbide A (BCRP) transport.	calcein AM	81-91	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
28807879-4	2017	Our results show that API increased ABCC1-mediated efflux of calcein-AM from uninfected erythrocytes, which was reversed with MK571, an inhibitor of ABCC1 drug efflux.	calcein AM	61-71	ATP binding cassette subfamily C member 1	Homo sapiens	36-41
28807879-4	2017	Our results show that API increased ABCC1-mediated efflux of calcein-AM from uninfected erythrocytes, which was reversed with MK571, an inhibitor of ABCC1 drug efflux.	calcein AM	61-71	ATP binding cassette subfamily C member 1	Homo sapiens	149-154
28899501-10	2017	The P-gp functional studies showed that these three alkaloids increased the accumulation of P-gp substrates, calcein-AM (C-AM) and rhodamine123 (Rho 123) in K562/Adr cells, while this effect was not seen in drug sensitive parental K562 cells.	calcein AM	121-125	phosphoglycolate phosphatase	Homo sapiens	4-8
28712845-5	2017	These agents block transporter mediated efflux of the P-gp substrate calcein-AM and the ABCG2 substrate mitoxantrone.	calcein AM	69-79	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
27864369-4	2017	Despite dramatic reduction in rhodamine 123 and calcein-AM transport, the linker-shortened mutant P-gp possesses basal ATPase activity and binds ATP only in its N-terminal nucleotide-binding domain.	calcein AM	48-58	phosphoglycolate phosphatase	Mus musculus	98-102
28628491-5	2017	Furthermore, we found that TopBP1, which we previously showed was involved in doxorubicin resistance through upregulation of aberrant p53, was involved in calcein-AM-mediated increased doxorubicin sensitivity.	calcein AM	155-165	DNA topoisomerase II binding protein 1	Homo sapiens	27-33
28628491-5	2017	Furthermore, we found that TopBP1, which we previously showed was involved in doxorubicin resistance through upregulation of aberrant p53, was involved in calcein-AM-mediated increased doxorubicin sensitivity.	calcein AM	155-165	tumor protein p53	Homo sapiens	134-137
28628491-7	2017	Calcein-AM repressed the expression of TopBP1, which resulted in reduced expression of aberrant p53 and disrupted the antiapoptotic activity mediated by the TopBP1/mutp53 pathway in NSCLC.	calcein AM	0-10	DNA topoisomerase II binding protein 1	Homo sapiens	39-45
28628491-7	2017	Calcein-AM repressed the expression of TopBP1, which resulted in reduced expression of aberrant p53 and disrupted the antiapoptotic activity mediated by the TopBP1/mutp53 pathway in NSCLC.	calcein AM	0-10	tumor protein p53	Homo sapiens	96-99
28628491-7	2017	Calcein-AM repressed the expression of TopBP1, which resulted in reduced expression of aberrant p53 and disrupted the antiapoptotic activity mediated by the TopBP1/mutp53 pathway in NSCLC.	calcein AM	0-10	DNA topoisomerase II binding protein 1	Homo sapiens	157-163
28628491-8	2017	Together, our findings show that calcein-AM, the cell-permeable derivative of calcein, exerts significant antitumor effects in NSCLC, and can enhance the antitumor effect of doxorubicin by regulating the TopBP1/mutp53 pathway.	calcein AM	33-43	DNA topoisomerase II binding protein 1	Homo sapiens	204-210
28405913-6	2017	While expression was similar, transport of calcein AM was enhanced in cells expressing the G3542T-, T3563A-, C3972T-, and G4544A-MRP2 variants.	calcein AM	43-53	ATP binding cassette subfamily C member 2	Homo sapiens	129-133
28405913-7	2017	By comparison, cells expressing the C2366T-MRP2 variant had 40-50% lower surface expression, which increased the accumulation of calcein AM up to 3-fold.	calcein AM	129-139	ATP binding cassette subfamily C member 2	Homo sapiens	43-47
28434113-5	2017	The EGFR siRNA RFE decreased cell viability, as measured by Calcein-AM measures, LDH release and Caspase 3 cleavage, and increased orthotopic xenograft survival.	calcein AM	60-70	epidermal growth factor receptor	Homo sapiens	4-8
27864141-0	2017	Long-term inhibition of cyclophilin D results in intracellular translocation of calcein AM from mitochondria to lysosomes.	calcein AM	80-90	peptidylprolyl isomerase D	Homo sapiens	24-37
27864141-3	2017	Here, we demonstrated the effects of cyclophilin D on the intracellular translocation of calcein AM.	calcein AM	89-99	peptidylprolyl isomerase D	Homo sapiens	37-50
27864141-4	2017	Following addition of calcein AM to control cells or cells overexpressing wild-type cyclophilin D, calcein fluorescence was observed in mitochondria.	calcein AM	22-32	peptidylprolyl isomerase D	Homo sapiens	84-97
29081884-4	2017	Our results showed that RSV or overexpression of SIRT1 elicited inhibitory effects on NMDA-induced excitotoxicity including a decrease in cell viability, an increase in lactate dehydrogenase (LDH) release, and a decrease in the number of living cells as measured by CCK-8 assay, LDH test, and Calcein-AM and PI double staining.	calcein AM	293-303	sirtuin 1	Homo sapiens	49-54
27810353-5	2017	In this work we present certain pyrrolo[3,2-d]pyrimidine derivatives with variations at positions 4 and 5 and purine analogs with variations at position 6 as novel activators of MRP1-mediated transport of the MRP1 substrate calcein AM and the anticancer drug daunorubicin in low nanomolar concentration range.	calcein AM	224-234	ATP binding cassette subfamily C member 1	Canis lupus familiaris	178-182
27810353-5	2017	In this work we present certain pyrrolo[3,2-d]pyrimidine derivatives with variations at positions 4 and 5 and purine analogs with variations at position 6 as novel activators of MRP1-mediated transport of the MRP1 substrate calcein AM and the anticancer drug daunorubicin in low nanomolar concentration range.	calcein AM	224-234	ATP binding cassette subfamily C member 1	Canis lupus familiaris	209-213
27131064-4	2016	Among these derivatives, 5a bearing on the 3-methylphenyl substituent, displayed the most potent P-gp inhibitory activity, which can enable the increase of the intracellular accumulation of P-gp substrate Calcein-AM.	calcein AM	205-215	phosphoglycolate phosphatase	Homo sapiens	97-101
30475507-6	2016	As a result of this combination treatment, two distinct patterns of interaction with P-gp activity were determined by a calcein-acetoxymethyl ester (AM) assay.	calcein AM	120-147	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
27154960-6	2016	Furthermore, we show functionality of translated P-gp protein in recipient cells using Calcein-AM dye exclusion assays on flow cytometry.	calcein AM	87-97	phosphoglycolate phosphatase	Homo sapiens	49-53
27131064-4	2016	Among these derivatives, 5a bearing on the 3-methylphenyl substituent, displayed the most potent P-gp inhibitory activity, which can enable the increase of the intracellular accumulation of P-gp substrate Calcein-AM.	calcein AM	205-215	phosphoglycolate phosphatase	Homo sapiens	190-194
26287374-13	2015	In addition induced P-gp transporter was shown to improve the efflux effect on colistin treated HK2 cell line, which was demonstrated by calcein-AM fluorescence accumulation assay.	calcein AM	137-147	ATP binding cassette subfamily B member 1	Homo sapiens	20-24
26887049-5	2016	LP117, the compound that exerted the strongest effect on ABCB1, interfered in the investigated concentrations of up to 2muM with the ABCB1-mediated transport of vincristine, vinorelbine, actinomycin D, paclitaxel, and calcein-AM but not of doxorubicin, rhodamine 123, or JC-1.	calcein AM	218-228	ATP binding cassette subfamily B member 1	Homo sapiens	133-138
27216424-6	2016	Based on the computational analysis, selected flavonoids were tested for their inhibitory potential against P-gp transport function in drug resistant cell lines using calcein-AM and rhodamine 123 efflux assays.	calcein AM	167-177	ATP binding cassette subfamily B member 1	Homo sapiens	108-112
26797828-4	2016	All compounds were characterized for their effect on P-gp, proving capable of blocking P-gp-mediated calcein-AM efflux with micromolar potency, following their ability to act as high-affinity substrates of this transporter.	calcein AM	101-111	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
26797828-4	2016	All compounds were characterized for their effect on P-gp, proving capable of blocking P-gp-mediated calcein-AM efflux with micromolar potency, following their ability to act as high-affinity substrates of this transporter.	calcein AM	101-111	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
26689174-3	2016	The accumulation of P-gp substrates, Calcein-AM, Rhodamine 123 and Doxorubicin, was significantly increased by 1J (up to 6-, 11- and 22- folds, respectively) and 2J (up to 7-, 12- and 17- folds, respectively).	calcein AM	37-47	phosphoglycolate phosphatase	Homo sapiens	20-24
26554512-4	2016	However, graphene and GO at the nontoxic concentrations could increase calcein-AM (CAM, an indicator of membrane ATP-binding cassette (ABC) transporter) activity) accumulation, indicating inhibition of ABC transporters" efflux capabilities.	calcein AM	71-81	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	135-138
25976226-5	2015	BCRP inhibition was observed in Hoechst 33342 and pheophorbide A assays while P-gp inhibition was evaluated in calcein AM and rhodamine-123 assays.	calcein AM	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
26070251-10	2015	This increased expression resulted also in an increased functional transport activity as measured by the P-gp mediated efflux of calcein AM.	calcein AM	129-139	phosphoglycolate phosphatase	Homo sapiens	105-109
26012726-4	2015	The mechanism of P-gp interaction for each compound was investigated with three biological assays: apparent permeability (Papp ) determination (B A/A B) in Caco-2 cell monolayers, ATP cell depletion, and inhibition of Calcein-AM transport in MDCK-MDR1 cells.	calcein AM	218-228	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
25907295-6	2015	A Calcein AM assay was used to quantify P-gp inhibition as determined by an increase in intracellular fluorescence.	calcein AM	2-12	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
28930203-6	2015	The inhibition of P-gp was determined by calcein-AM uptake method in transfected and wild type MDCKII cells.	calcein AM	41-51	PGP	Canis lupus familiaris	18-22
24375866-5	2014	The calcein-acetoxymethyl ester (calcein-AM) assay commonly used in pharmacological research was established with P-gp-overexpressing Madin-Darby canine kidney cells (MDCKII-MDR1) in a 96-well plate, avoiding extra washing, centrifugation, and lysis steps.	calcein AM	4-31	PGP	Canis lupus familiaris	114-118
25265513-3	2015	The P-gp functional studies showed that the STFD increased the accumulation of calcein-AM, rhodamine 123 and [(14) C]-doxorubicin in K562/Adr cells, while the effects have not been seen in their parental sensitive cancer cell line (K562).	calcein AM	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
25802484-10	2015	After calcein AM was administered, it was cleaved by an esterase into a fluorescent product that is normally transported out of the cell by ABCB1.	calcein AM	6-16	ATP binding cassette subfamily B member 1	Homo sapiens	140-145
25400145-5	2014	Calcein AM, the cell-permeable derivative of calcein, shows significant antitumour activity in a wide spectrum of cultured cancer cells harbouring high TopBP1 levels.	calcein AM	0-10	DNA topoisomerase II binding protein 1	Homo sapiens	152-158
25192198-7	2014	We showed that GSK461364 stimulates the ABCB1 ATPase activity and competitively inhibits ABCB1-mediated efflux of calcein-AM in a concentration-dependent manner.	calcein AM	114-124	ATP binding cassette subfamily B member 1	Homo sapiens	89-94
24907976-3	2014	They were further investigated for their influence on the cell cycle of KB-V1/Vbl and HCT-116 colon carcinoma cells, on the generation of reactive oxygen species (ROS) by the latter cell line, for their substrate character for the P-glycoprotein drug eflux pump via the calcein-AM efflux assays, and for DNA affinity by the electrophoretic mobility shift assay (EMSA).	calcein AM	270-280	ATP binding cassette subfamily B member 1	Homo sapiens	231-245
24907976-7	2014	While plumbagin did not affect calcein-AM transport by P-glycoprotein the derivatives 1c and 2a exhibited a 50% or 80% inhibition of the P-glycoprotein-mediated calcein-AM efflux relative to the clinically established sensitizer verapamil.	calcein AM	161-171	ATP binding cassette subfamily B member 1	Homo sapiens	137-151
24949819-14	2014	P-glycoprotein (P-gp) interaction for indolinone was studied with the aid of a calcein-AM uptake assay, and by calculation of the efflux ratio (ER) from the bidirectional permeability assays.	calcein AM	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
24949819-14	2014	P-glycoprotein (P-gp) interaction for indolinone was studied with the aid of a calcein-AM uptake assay, and by calculation of the efflux ratio (ER) from the bidirectional permeability assays.	calcein AM	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
24954033-3	2014	The function of ABCB1 and ABCG2 was confirmed using calcein AM and pheophorbide A accumulation assays, respectively.	calcein AM	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	16-21
24954033-3	2014	The function of ABCB1 and ABCG2 was confirmed using calcein AM and pheophorbide A accumulation assays, respectively.	calcein AM	52-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	26-31
24641346-3	2014	When incubated with calcein-AM, a substrate of the efflux transporter P-glycoprotein (Pgp), spheroids from a variety of cell types accumulated calcein over time.	calcein AM	20-30	ATP binding cassette subfamily B member 1	Homo sapiens	70-84
24641346-3	2014	When incubated with calcein-AM, a substrate of the efflux transporter P-glycoprotein (Pgp), spheroids from a variety of cell types accumulated calcein over time.	calcein AM	20-30	ATP binding cassette subfamily B member 1	Homo sapiens	86-89
24690257-6	2014	ABCB1 transporter (PGP1) inhibition was assessed using the acetomethoxy derivate of calcein (calcein-AM) as a fluorescent probe in both wild-type MDCKII and PGP1 overexpressing MDCKII cells.	calcein AM	93-103	ATP binding cassette subfamily B member 1	Canis lupus familiaris	0-5
24690257-6	2014	ABCB1 transporter (PGP1) inhibition was assessed using the acetomethoxy derivate of calcein (calcein-AM) as a fluorescent probe in both wild-type MDCKII and PGP1 overexpressing MDCKII cells.	calcein AM	93-103	CD44 molecule	Canis lupus familiaris	19-23
24690257-6	2014	ABCB1 transporter (PGP1) inhibition was assessed using the acetomethoxy derivate of calcein (calcein-AM) as a fluorescent probe in both wild-type MDCKII and PGP1 overexpressing MDCKII cells.	calcein AM	93-103	CD44 molecule	Canis lupus familiaris	157-161
24873950-4	2014	We show how the MTNP platform can be used for hematologic cancer cell characterization by measuring single T cell levels of CRAC channel modulation, non-translational motility, and ABC-transporter inhibition via a calcein-AM efflux assay.	calcein AM	214-224	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	181-196
24375866-5	2014	The calcein-acetoxymethyl ester (calcein-AM) assay commonly used in pharmacological research was established with P-gp-overexpressing Madin-Darby canine kidney cells (MDCKII-MDR1) in a 96-well plate, avoiding extra washing, centrifugation, and lysis steps.	calcein AM	4-31	ATP binding cassette subfamily B member 1	Canis lupus familiaris	167-178
24375866-5	2014	The calcein-acetoxymethyl ester (calcein-AM) assay commonly used in pharmacological research was established with P-gp-overexpressing Madin-Darby canine kidney cells (MDCKII-MDR1) in a 96-well plate, avoiding extra washing, centrifugation, and lysis steps.	calcein AM	33-43	PGP	Canis lupus familiaris	114-118
24375866-5	2014	The calcein-acetoxymethyl ester (calcein-AM) assay commonly used in pharmacological research was established with P-gp-overexpressing Madin-Darby canine kidney cells (MDCKII-MDR1) in a 96-well plate, avoiding extra washing, centrifugation, and lysis steps.	calcein AM	33-43	ATP binding cassette subfamily B member 1	Canis lupus familiaris	167-178
24375866-6	2014	This calcein-AM-based P-gp cellular efflux pump inhibition assay (CEPIA) was used to study the inhibition by commonly occurring environmental contaminants.	calcein AM	5-15	PGP	Canis lupus familiaris	22-26
24375866-7	2014	Among others, the compounds pentachlorophenol, perfluorooctane sulfonate, and perfluorooctanoate strongly inhibited the P-gp-mediated efflux of calcein-AM while the chloninated alkanes did not seem to interact with the transporter.	calcein AM	144-154	PGP	Canis lupus familiaris	120-124
24314882-6	2014	TSP-1-induced migration was assessed with a modified Boyden microchemotaxis chamber and proliferation with calcein-AM fluorescence.	calcein AM	107-117	thrombospondin 1	Homo sapiens	0-5
24532159-6	2014	Pgp function was investigated applying the Calcein-AM assay as well as bidirectional transport assays using (3) H-Digoxin, (3) H-Vinblastine, and (3) H-Quinidine as substrates.	calcein AM	43-53	PGP	Canis lupus familiaris	0-3
24521085-4	2014	The P-gp interacting properties were evaluated measuring the effects of thiolated- and unmodified-polymers on the bidirectional transport (BA/AB) of rhodamine-123 across Caco-2 cells as well as in the calcein-AM and ATPase activity assays.	calcein AM	201-211	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
23994641-7	2013	The potential P-gp (P-glycoprotein) interaction for E804 was determined through Calcein-AM uptake assay.	calcein AM	80-90	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
23999162-4	2013	Selected SM increased the accumulation of the rhodamine 123 (Rho123) and calcein-AM (CAM) in a dose dependent manner in Caco-2 cells, indicating that they act as competitive inhibitors of P-gp.	calcein AM	85-88	phosphoglycolate phosphatase	Homo sapiens	188-192
23994641-7	2013	The potential P-gp (P-glycoprotein) interaction for E804 was determined through Calcein-AM uptake assay.	calcein AM	80-90	ATP binding cassette subfamily B member 1	Homo sapiens	20-34
23879966-8	2013	VPA17 cells had increased Pgp-mediated efflux of calcein acetoxymethyl ester (calcein AM); however, this was inhibited in cells pre-incubated in silibinin for 5 days.	calcein AM	49-76	phosphoglycolate phosphatase	Homo sapiens	26-29
24098380-8	2013	Furthermore, calcein-AM dye-efflux assays using HBMVEC showed that, compared to virus exposure alone, the MDR1 mediated drug-efflux function was significantly induced following concomitant exposure to both HIV-1 and saquinavir (SQV).	calcein AM	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	106-110
23879966-8	2013	VPA17 cells had increased Pgp-mediated efflux of calcein acetoxymethyl ester (calcein AM); however, this was inhibited in cells pre-incubated in silibinin for 5 days.	calcein AM	78-88	phosphoglycolate phosphatase	Homo sapiens	26-29
24058883-7	2013	CBD impact on P-gp efflux function was examined by uptake of specific P-gp fluorescent substrates (calcein-AM, DiOC2(3) and rhodamine123(rh123)).	calcein AM	99-109	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
24058883-7	2013	CBD impact on P-gp efflux function was examined by uptake of specific P-gp fluorescent substrates (calcein-AM, DiOC2(3) and rhodamine123(rh123)).	calcein AM	99-109	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
23680234-7	2013	Lastly, by combining the TACs/Sep NK cell isolation method with calcein-acetoxymethyl diacetylester (calcein-AM) release, the time required to assess in vitro cytotoxicity was reduced by 33% (4h) compared to protocols employing DG/MACS and chromium release.	calcein AM	101-111	Ras and Rab interactor 2	Homo sapiens	231-235
23851114-6	2013	All the compounds were further screened for their P-glycoprotein (P-gp) and Multidrug resistance-associated protein 1 (MRP1) inhibitory activity by calcein AM accumulation assay to check the selectivity towards BCRP.	calcein AM	148-158	ATP binding cassette subfamily C member 1	Canis lupus familiaris	119-123
24900683-4	2013	Inhibition of ABCB1 and ABCG2 was determined in a calcein-AM and a Hoechst 33342 microplate assay, respectively.	calcein AM	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	14-19
23731729-8	2013	There was an inverse correlation between Pgp1 expression and Calcein-AM uptake.	calcein AM	61-71	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
23593196-6	2013	Validation of the assay was performed with known ABCB1 inhibitors, XR9576, verapamil, and cyclosporin A, all of which displayed dose-dependent inhibition of ABCB1-mediated calcein AM efflux in this assay.	calcein AM	172-182	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
23593196-6	2013	Validation of the assay was performed with known ABCB1 inhibitors, XR9576, verapamil, and cyclosporin A, all of which displayed dose-dependent inhibition of ABCB1-mediated calcein AM efflux in this assay.	calcein AM	172-182	ATP binding cassette subfamily B member 1	Homo sapiens	157-162
24900683-4	2013	Inhibition of ABCB1 and ABCG2 was determined in a calcein-AM and a Hoechst 33342 microplate assay, respectively.	calcein AM	50-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	24-29
22942241-6	2012	Intracellular retention of fluorescent rhodamine 123, Hoechst 33342, and calcein acetoxymethyl ester was increased in LPS-treated microglia, suggesting that the functions of Mdr1, Bcrp, and Mrps were decreased, respectively.	calcein AM	73-100	toll-like receptor 4	Mus musculus	118-121
23278697-3	2013	METHODS: The activity of P-gp and MRP2 was determined in the uptake assays by monitoring the intracellular accumulation of their specific substrates (calcein acetoxymethyl ester and 5(6)-carboxy-2",7"-dichlorofluorescein diacetate, respectively) with fluorescence spectroscopy.	calcein AM	150-177	ATP binding cassette subfamily B member 1	Homo sapiens	25-29
23278697-3	2013	METHODS: The activity of P-gp and MRP2 was determined in the uptake assays by monitoring the intracellular accumulation of their specific substrates (calcein acetoxymethyl ester and 5(6)-carboxy-2",7"-dichlorofluorescein diacetate, respectively) with fluorescence spectroscopy.	calcein AM	150-177	ATP binding cassette subfamily C member 2	Homo sapiens	34-38
22727780-1	2012	Twelve thiorhodamine derivatives have been examined for their ability to stimulate the ATPase activity of purified human P-glycoprotein (P-gp)-His(10), to promote uptake of calcein AM and vinblastine into multidrug-resistant, P-gp-overexpressing MDCKII-MDR1 cells, and for their rates of transport in monolayers of multidrug-resistant, P-gp-overexpressing MDCKII-MDR1 cells.	calcein AM	173-183	ATP binding cassette subfamily B member 1	Homo sapiens	121-135
22819804-5	2012	MK571, a known inhibitor of mammalian ABCC transporters, blocks efflux of calcein-am in larvae and gill tissue as indicated by elevated calcein fluorescence; this indicates the presence of active Abcc protein in cells of the larvae and gills.	calcein AM	74-84	ATP binding cassette subfamily C member 1	Homo sapiens	38-42
22819804-5	2012	MK571, a known inhibitor of mammalian ABCC transporters, blocks efflux of calcein-am in larvae and gill tissue as indicated by elevated calcein fluorescence; this indicates the presence of active Abcc protein in cells of the larvae and gills.	calcein AM	74-84	ATP binding cassette subfamily C member 1	Homo sapiens	196-200
22819804-6	2012	Dacthal and mercury used as chemical stressors both induced expression of abcb1 and abcc mRNAs in larvae; accordingly, assays with calcein-am and ABCB1 inhibitor reversin 205 and ABCC inhibitor MK571 indicated enhanced Abcb1 and Abcc efflux activities.	calcein AM	131-141	ATP binding cassette subfamily C member 1	Homo sapiens	84-88
22727780-1	2012	Twelve thiorhodamine derivatives have been examined for their ability to stimulate the ATPase activity of purified human P-glycoprotein (P-gp)-His(10), to promote uptake of calcein AM and vinblastine into multidrug-resistant, P-gp-overexpressing MDCKII-MDR1 cells, and for their rates of transport in monolayers of multidrug-resistant, P-gp-overexpressing MDCKII-MDR1 cells.	calcein AM	173-183	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
22353810-4	2012	Viable mitochondria were isolated and MRP-1 efflux activity measured using the calcein-AM functional assay.	calcein AM	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
22632934-3	2012	Calcein-AM substrate accumulation assays were performed in an MCF7/DX1 cell line that overexpresses P-gp to monitor the inhibitory activity of the clicked quinine dimers.	calcein AM	0-10	phosphoglycolate phosphatase	Homo sapiens	100-104
22661920-3	2012	Herein, we report that calcein AM (the calcein acetoxymethyl-ester) is a potent specific inhibitor of CDK4 and CDK6 in HCT116 human colon adenocarcinoma cells, inhibiting retinoblastoma protein (pRb) phosphorylation and inducing cell cycle arrest in the G(1) phase.	calcein AM	23-33	cyclin dependent kinase 4	Homo sapiens	102-106
22661920-3	2012	Herein, we report that calcein AM (the calcein acetoxymethyl-ester) is a potent specific inhibitor of CDK4 and CDK6 in HCT116 human colon adenocarcinoma cells, inhibiting retinoblastoma protein (pRb) phosphorylation and inducing cell cycle arrest in the G(1) phase.	calcein AM	23-33	cyclin dependent kinase 6	Homo sapiens	111-115
22661920-3	2012	Herein, we report that calcein AM (the calcein acetoxymethyl-ester) is a potent specific inhibitor of CDK4 and CDK6 in HCT116 human colon adenocarcinoma cells, inhibiting retinoblastoma protein (pRb) phosphorylation and inducing cell cycle arrest in the G(1) phase.	calcein AM	23-33	RB transcriptional corepressor 1	Homo sapiens	195-198
22661920-3	2012	Herein, we report that calcein AM (the calcein acetoxymethyl-ester) is a potent specific inhibitor of CDK4 and CDK6 in HCT116 human colon adenocarcinoma cells, inhibiting retinoblastoma protein (pRb) phosphorylation and inducing cell cycle arrest in the G(1) phase.	calcein AM	39-66	cyclin dependent kinase 4	Homo sapiens	102-106
22661920-3	2012	Herein, we report that calcein AM (the calcein acetoxymethyl-ester) is a potent specific inhibitor of CDK4 and CDK6 in HCT116 human colon adenocarcinoma cells, inhibiting retinoblastoma protein (pRb) phosphorylation and inducing cell cycle arrest in the G(1) phase.	calcein AM	39-66	cyclin dependent kinase 6	Homo sapiens	111-115
22661920-3	2012	Herein, we report that calcein AM (the calcein acetoxymethyl-ester) is a potent specific inhibitor of CDK4 and CDK6 in HCT116 human colon adenocarcinoma cells, inhibiting retinoblastoma protein (pRb) phosphorylation and inducing cell cycle arrest in the G(1) phase.	calcein AM	39-66	RB transcriptional corepressor 1	Homo sapiens	195-198
22661920-6	2012	The results show that the metabolic profile associated with the depletion of CDK4, CDK6 and CDK2 coincides with the metabolic changes induced by calcein AM on HCT116 cells, thus confirming that the inhibition of CDK4 and CDK6 disrupts the balance between the oxidative and non-oxidative branches of the pentose phosphate pathway.	calcein AM	145-155	cyclin dependent kinase 4	Homo sapiens	77-81
22661920-6	2012	The results show that the metabolic profile associated with the depletion of CDK4, CDK6 and CDK2 coincides with the metabolic changes induced by calcein AM on HCT116 cells, thus confirming that the inhibition of CDK4 and CDK6 disrupts the balance between the oxidative and non-oxidative branches of the pentose phosphate pathway.	calcein AM	145-155	cyclin dependent kinase 6	Homo sapiens	83-87
22661920-6	2012	The results show that the metabolic profile associated with the depletion of CDK4, CDK6 and CDK2 coincides with the metabolic changes induced by calcein AM on HCT116 cells, thus confirming that the inhibition of CDK4 and CDK6 disrupts the balance between the oxidative and non-oxidative branches of the pentose phosphate pathway.	calcein AM	145-155	cyclin dependent kinase 2	Homo sapiens	92-96
22661920-6	2012	The results show that the metabolic profile associated with the depletion of CDK4, CDK6 and CDK2 coincides with the metabolic changes induced by calcein AM on HCT116 cells, thus confirming that the inhibition of CDK4 and CDK6 disrupts the balance between the oxidative and non-oxidative branches of the pentose phosphate pathway.	calcein AM	145-155	cyclin dependent kinase 4	Homo sapiens	212-216
22661920-6	2012	The results show that the metabolic profile associated with the depletion of CDK4, CDK6 and CDK2 coincides with the metabolic changes induced by calcein AM on HCT116 cells, thus confirming that the inhibition of CDK4 and CDK6 disrupts the balance between the oxidative and non-oxidative branches of the pentose phosphate pathway.	calcein AM	145-155	cyclin dependent kinase 6	Homo sapiens	221-225
22066701-9	2012	Calcein AM-labeled PMNs were co-cultured with TNF-alpha-stimulated rat lung microvascular endothelial cells, and their ability to adhere was assessed by fluorometry and digital imaging and finally, chemotaxis was measured by neutrophil transmigration assays.	calcein AM	0-10	tumor necrosis factor	Rattus norvegicus	46-55
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	calcein AM	72-98	MIR7-3 host gene	Homo sapiens	0-5
22079615-7	2012	In addition, induced P-gp transporter was shown to improve the efflux effect on PQ-treated A549 cell lines as was demonstrated using the Calcein-AM fluorescence accumulation assay.	calcein AM	137-147	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
23037162-3	2012	We assessed the effects of 26 kinds of Kampo medicine on MDR-1 by calcein-AM efflux assay using HuH-7/PTX cells, and the results revealed that takushato and goreisan are potential inhibitors of drug efflux by MDR-1.	calcein AM	66-76	ATP binding cassette subfamily B member 1	Homo sapiens	57-62
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	calcein AM	72-98	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
23037162-3	2012	We assessed the effects of 26 kinds of Kampo medicine on MDR-1 by calcein-AM efflux assay using HuH-7/PTX cells, and the results revealed that takushato and goreisan are potential inhibitors of drug efflux by MDR-1.	calcein AM	66-76	MIR7-3 host gene	Homo sapiens	96-101
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	calcein AM	72-98	MIR7-3 host gene	Homo sapiens	160-165
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	calcein AM	72-98	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	calcein AM	100-110	MIR7-3 host gene	Homo sapiens	0-5
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	calcein AM	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	calcein AM	100-110	MIR7-3 host gene	Homo sapiens	160-165
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	calcein AM	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
22112540-8	2012	The compounds were also screened for their P-glycoprotein (P-gp) and Multidrug resistance-associated protein 1 (MRP1) inhibitory activity in the calcein AM accumulation assay and were found to be selective towards inhibition of BCRP.	calcein AM	145-155	ATP binding cassette subfamily C member 1	Homo sapiens	112-116
22112540-8	2012	The compounds were also screened for their P-glycoprotein (P-gp) and Multidrug resistance-associated protein 1 (MRP1) inhibitory activity in the calcein AM accumulation assay and were found to be selective towards inhibition of BCRP.	calcein AM	145-155	ATP binding cassette subfamily B member 1	Homo sapiens	43-57
22112540-8	2012	The compounds were also screened for their P-glycoprotein (P-gp) and Multidrug resistance-associated protein 1 (MRP1) inhibitory activity in the calcein AM accumulation assay and were found to be selective towards inhibition of BCRP.	calcein AM	145-155	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
22112540-8	2012	The compounds were also screened for their P-glycoprotein (P-gp) and Multidrug resistance-associated protein 1 (MRP1) inhibitory activity in the calcein AM accumulation assay and were found to be selective towards inhibition of BCRP.	calcein AM	145-155	ATP binding cassette subfamily C member 1	Homo sapiens	69-110
22112540-8	2012	The compounds were also screened for their P-glycoprotein (P-gp) and Multidrug resistance-associated protein 1 (MRP1) inhibitory activity in the calcein AM accumulation assay and were found to be selective towards inhibition of BCRP.	calcein AM	145-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	228-232
20676745-3	2011	The efflux function of P-glycoprotein was evaluated by rhodamine 123 accumulation and calcein-AM uptake models.	calcein AM	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	23-37
21414769-6	2012	A flow cytometry assay indicated that kuguacin J inhibits the transport function of P-gp and thereby significantly increases the accumulation of rhodamine 123 and calcein AM in the cells.	calcein AM	163-173	phosphoglycolate phosphatase	Homo sapiens	84-88
22563480-4	2012	Calcein-AM uptake was measured as fluorescence intensity changes in the presence of Pgp or MRP specific inhibitors.	calcein AM	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	84-87
22563480-4	2012	Calcein-AM uptake was measured as fluorescence intensity changes in the presence of Pgp or MRP specific inhibitors.	calcein AM	0-10	ATP binding cassette subfamily C member 2	Rattus norvegicus	91-94
21321059-7	2011	In addition, spinosad was a strong inhibitor of the P-gp transport of digoxin, calcein acetoxymethyl ester (IC(50) = 3.2 muM), and ivermectin (IC(50) = 2.3 muM).	calcein AM	79-106	PGP	Canis lupus familiaris	52-56
21864659-4	2011	Cellular accumulation of calcein-AM was further determined to confirm the affinity of gemifloxacin towards P-gp and MRP2.	calcein AM	25-35	phosphoglycolate phosphatase	Homo sapiens	107-111
21864659-4	2011	Cellular accumulation of calcein-AM was further determined to confirm the affinity of gemifloxacin towards P-gp and MRP2.	calcein AM	25-35	ATP binding cassette subfamily C member 2	Homo sapiens	116-120
24309308-6	2011	P-gp-mediated transport was measured by using the P-gp substrate calcein-AM in the presence and absence of the P-gp-inhibitor PSC833.	calcein AM	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
24309308-6	2011	P-gp-mediated transport was measured by using the P-gp substrate calcein-AM in the presence and absence of the P-gp-inhibitor PSC833.	calcein AM	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
24309308-6	2011	P-gp-mediated transport was measured by using the P-gp substrate calcein-AM in the presence and absence of the P-gp-inhibitor PSC833.	calcein AM	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
21570282-4	2011	Among these esters highly potent and selective ABCG2 modulators were identified (inhibition of ABCB1 and ABCG2 determined in the calcein-AM and the Hoechst 33342 microplate assay, respectively).	calcein AM	129-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	47-52
21570282-4	2011	Among these esters highly potent and selective ABCG2 modulators were identified (inhibition of ABCB1 and ABCG2 determined in the calcein-AM and the Hoechst 33342 microplate assay, respectively).	calcein AM	129-139	ATP binding cassette subfamily B member 1	Homo sapiens	95-100
21570282-4	2011	Among these esters highly potent and selective ABCG2 modulators were identified (inhibition of ABCB1 and ABCG2 determined in the calcein-AM and the Hoechst 33342 microplate assay, respectively).	calcein AM	129-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	105-110
19860126-7	2009	Cell cultures from Msx2 deficient mice showed lower intensity of fluorescence when marked with Calcein AM then cultures from wild type mice.	calcein AM	95-105	msh homeobox 2	Mus musculus	19-23
21239442-5	2011	After treatment, P-gp function was assessed using calcein-acetoxymethyl ester (P-gp substrate; 1 mum for 1 h) and measuring BEC accumulation of calcein.	calcein AM	50-77	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
20704740-7	2010	Functionality of P-gp and Mrp1 was confirmed by Calcein-AM and CMFDA uptake assays and studies using [3H]bis-POM-PMEA as a substrate indicated Mrp4 function.	calcein AM	48-58	phosphoglycolate phosphatase	Rattus norvegicus	17-21
20704740-7	2010	Functionality of P-gp and Mrp1 was confirmed by Calcein-AM and CMFDA uptake assays and studies using [3H]bis-POM-PMEA as a substrate indicated Mrp4 function.	calcein AM	48-58	ATP binding cassette subfamily C member 1	Rattus norvegicus	26-30
19879740-7	2010	However, calcein-AM uptake into the human P-gp overexpression cell line, LLC-GA5-COL300, was increased by curcumin and demethoxycurcumin in a concentration-dependent manner but not affected by bisdemethoxycurcumin.	calcein AM	9-19	phosphoglycolate phosphatase	Homo sapiens	42-46
21302361-1	2011	The ability of aurones to modulate the efflux activities of ABCG2 and ABCB1 was investigated by quantifying their effects on the accumulation of pheophorbide A (PhA) in ABCG2-overexpressing MDA-MB-231/R cells and calcein AM in ABCB1-overexpressing MDCKII/MDR1 cells.	calcein AM	213-223	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	60-65
21804213-5	2011	Then, we evaluated the effect of these furanocoumarins on the uptake of calcein acetoxymethyl ester (calcein-AM), a P-gp substrate, into bovine brain microvascular endothelial cells (BBMEC).	calcein AM	72-99	phosphoglycolate phosphatase	Bos taurus	116-120
21804213-5	2011	Then, we evaluated the effect of these furanocoumarins on the uptake of calcein acetoxymethyl ester (calcein-AM), a P-gp substrate, into bovine brain microvascular endothelial cells (BBMEC).	calcein AM	101-111	phosphoglycolate phosphatase	Bos taurus	116-120
21804213-6	2011	Both furanocoumarins significantly increased the uptake amount of calcein-AM into BBMEC by the inhibition of P-gp at the BBB in vitro.	calcein AM	66-76	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	109-113
19682511-2	2009	In this study, we found that HBx expression in the absence of other HBV proteins and in the context of HBV replication decreased the mitochondrial calcein-AM/CoCl(2) signals by 10% and 14% in HepG2 cells and by 15% and 10% in Huh7 cells, respectively.	calcein AM	147-157	X protein	Hepatitis B virus	29-32
19823672-7	2009	Additionally, NSC23925 increases the intracellular accumulation of Pgp1 substrates: calcein AM, Rhodamine-123, paclitaxel, mitoxantrone, and doxorubicin.	calcein AM	84-94	CD44 molecule (Indian blood group)	Homo sapiens	67-71
19721237-13	2009	DRV inhibited P-glycoprotein-mediated efflux of calcein-acetoxymethyl ester in L-MDR1 cells with the inhibitory potency of 121 microM.	calcein AM	48-75	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
19721237-13	2009	DRV inhibited P-glycoprotein-mediated efflux of calcein-acetoxymethyl ester in L-MDR1 cells with the inhibitory potency of 121 microM.	calcein AM	48-75	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
19107236-6	2009	In Madin-Darby canine kidney II cells engineered to overexpress Pgp or MRP1, HhAntag691 increased the retention of calcein-AM and resensitized them to colchicine.	calcein AM	115-125	PGP	Canis lupus familiaris	64-67
19239227-5	2009	In parallel to the alteration in gene expression, functional activity studies indicated that the cellular uptake of benzoic acid, MPP+, calcein-AM, H33342, representative substrates of MCT1, OCT1, MRPs and BCRP, respectively, was significantly (p < 0.05) altered by c-Myc overexpression.	calcein AM	136-146	solute carrier family 16 member 1	Homo sapiens	185-189
19239227-5	2009	In parallel to the alteration in gene expression, functional activity studies indicated that the cellular uptake of benzoic acid, MPP+, calcein-AM, H33342, representative substrates of MCT1, OCT1, MRPs and BCRP, respectively, was significantly (p < 0.05) altered by c-Myc overexpression.	calcein AM	136-146	solute carrier family 22 member 1	Homo sapiens	191-195
19239227-5	2009	In parallel to the alteration in gene expression, functional activity studies indicated that the cellular uptake of benzoic acid, MPP+, calcein-AM, H33342, representative substrates of MCT1, OCT1, MRPs and BCRP, respectively, was significantly (p < 0.05) altered by c-Myc overexpression.	calcein AM	136-146	BCR pseudogene 1	Homo sapiens	206-210
19239227-5	2009	In parallel to the alteration in gene expression, functional activity studies indicated that the cellular uptake of benzoic acid, MPP+, calcein-AM, H33342, representative substrates of MCT1, OCT1, MRPs and BCRP, respectively, was significantly (p < 0.05) altered by c-Myc overexpression.	calcein AM	136-146	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	269-274
19739602-1	2009	Oroxylin A (1), a flavonoid from the roots of Scutellaria baicalensis, increased the cellular accumulation of calcein AM in a concentration-dependent manner in NCI/ADR-RES cells overexpressing P-glycoprotein over the concentration range 0-40 microM.	calcein AM	110-120	ATP binding cassette subfamily B member 1	Homo sapiens	193-207
19384462-3	2009	Furthermore, activity of MRP1 and MRP5 of ARPE-19 cell line was assessed with calcein-AM and carboxydichlorofluorescein (CDCF) probes.	calcein AM	78-88	MDM4 regulator of p53	Homo sapiens	25-29
19384462-3	2009	Furthermore, activity of MRP1 and MRP5 of ARPE-19 cell line was assessed with calcein-AM and carboxydichlorofluorescein (CDCF) probes.	calcein AM	78-88	ATP binding cassette subfamily C member 5	Homo sapiens	34-38
19384462-8	2009	The calcein-AM and CDCF efflux tests provided evidence supporting MRP1 and MRP5 activity in ARPE-19 cells.	calcein AM	4-14	MDM4 regulator of p53	Homo sapiens	66-70
19384462-8	2009	The calcein-AM and CDCF efflux tests provided evidence supporting MRP1 and MRP5 activity in ARPE-19 cells.	calcein AM	4-14	ATP binding cassette subfamily C member 5	Homo sapiens	75-79
19285492-5	2009	The effect on P-gp activity was analysed using the calcein-AM accumulation assay where a multidrug activity factor (MAF) of >10 in the presence of a P-gp inhibitor denotes P-gp functional activity.	calcein AM	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
19285492-5	2009	The effect on P-gp activity was analysed using the calcein-AM accumulation assay where a multidrug activity factor (MAF) of >10 in the presence of a P-gp inhibitor denotes P-gp functional activity.	calcein AM	51-61	MAF bZIP transcription factor	Homo sapiens	116-119
19285492-5	2009	The effect on P-gp activity was analysed using the calcein-AM accumulation assay where a multidrug activity factor (MAF) of >10 in the presence of a P-gp inhibitor denotes P-gp functional activity.	calcein AM	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	152-156
19285492-5	2009	The effect on P-gp activity was analysed using the calcein-AM accumulation assay where a multidrug activity factor (MAF) of >10 in the presence of a P-gp inhibitor denotes P-gp functional activity.	calcein AM	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	152-156
19107236-6	2009	In Madin-Darby canine kidney II cells engineered to overexpress Pgp or MRP1, HhAntag691 increased the retention of calcein-AM and resensitized them to colchicine.	calcein AM	115-125	ATP binding cassette subfamily C member 1	Canis lupus familiaris	71-75
19291917-4	2008	The expression and functional activities were examined using flow cytometry and MultiDrugQuant assay kit (involving calcein AM uptake and efflux).	calcein AM	116-126	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	101-104
19008001-6	2008	In addition, the presence of Pgp1-, BSEP- and MRP-like transport activities were indicated using putative specific fluorescent substrates (rhodamine 123, calcein-AM, bodipy-verapamil and dihydrofluorescein diacetat), model inhibitors (verapamil, cyclosporine A, MK571, reversine 205, taurocholate and taurochenodeoxycholate) and their combinations.	calcein AM	154-164	CD44 molecule (Indian blood group)	Homo sapiens	29-33
19008001-6	2008	In addition, the presence of Pgp1-, BSEP- and MRP-like transport activities were indicated using putative specific fluorescent substrates (rhodamine 123, calcein-AM, bodipy-verapamil and dihydrofluorescein diacetat), model inhibitors (verapamil, cyclosporine A, MK571, reversine 205, taurocholate and taurochenodeoxycholate) and their combinations.	calcein AM	154-164	ATP binding cassette subfamily B member 11	Homo sapiens	36-40
18981572-3	2008	Human monocytic THP-1 cells labeled with fluorescent dye (Calcein-AM) was used for the adhesion assay on HUVEC monolayers.	calcein AM	58-68	GLI family zinc finger 2	Homo sapiens	16-21
18849167-3	2008	Their ability to promote calcein-AM (CAM) uptake in MDCKII-MDR1 cells and their capacity to be transported by Pgp in monolayers of MDCKII-MDR1 cells were also evaluated.	calcein AM	37-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-63
18849167-4	2008	The chalcogenopyrylium dyes promoted CAM uptake with values of EC(50) between 5 x 10(-6) and 3.5 x 10(-5)M and 7 of the 9 dyes examined in transport studies were substrates for Pgp with efflux ratios (P(BA/AB)) between 14 and 390.	calcein AM	37-40	phosphoglycolate phosphatase	Mus musculus	177-180
18725288-6	2008	The aurones (10 microM) also increased calcein-AM accumulation in MDCKII/MDR1 cells that were transfected with ABCB1 (P-glycoprotein), at levels comparable to verapamil tested at the same concentration.	calcein AM	39-49	ATP binding cassette subfamily B member 1	Canis lupus familiaris	111-116
18408562-3	2008	METHODS AND RESULTS: Transport of substrate rhodamine 123 and calcein-AM by human Pgp carrying 12 haplotype combinations of 1236C>T, 2677G>T/A and 3435C>T were assayed in the absence and presence of known inhibitors and AEDs.	calcein AM	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	82-85
18396325-4	2008	Calcein-am acts as a substrate of both P-gp and MRP.	calcein AM	0-10	ATP binding cassette subfamily C member 3	Homo sapiens	48-51
18401003-4	2008	Activity of ABCB/MDR/P-glycoprotein and ABCC/MRP-type transporters was indicated by sensitivity of efflux of the test substrate calcein-AM to the ABCB inhibitor PSC-833 and the ABCC inhibitor MK-571.	calcein AM	128-138	ATP binding cassette subfamily C member 1	Homo sapiens	40-44
18401003-4	2008	Activity of ABCB/MDR/P-glycoprotein and ABCC/MRP-type transporters was indicated by sensitivity of efflux of the test substrate calcein-AM to the ABCB inhibitor PSC-833 and the ABCC inhibitor MK-571.	calcein AM	128-138	ATP binding cassette subfamily C member 1	Homo sapiens	45-48
18401003-4	2008	Activity of ABCB/MDR/P-glycoprotein and ABCC/MRP-type transporters was indicated by sensitivity of efflux of the test substrate calcein-AM to the ABCB inhibitor PSC-833 and the ABCC inhibitor MK-571.	calcein AM	128-138	ATP binding cassette subfamily C member 1	Homo sapiens	177-181
18396325-4	2008	Calcein-am acts as a substrate of both P-gp and MRP.	calcein AM	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	39-43
17261498-5	2007	MRP1 function was evaluated by measuring calcein acetoxymethyl ester (calcein-AM) efflux, and by verifying its inhibition by MK571, a potent MRP inhibitor.	calcein AM	41-68	ATP binding cassette subfamily C member 1	Homo sapiens	0-4
17697617-0	2007	[Evaluation of the P-gp pump function on leukemic cell membrane and proper application of its reversal agents with Calcein-AM and flow cytometry].	calcein AM	115-125	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
17697617-11	2007	In addition, the MFI of the C-AM in K562 was significantly higher than that in K562/VCR cells indicating that the P-gp pump molecules were functioning.	calcein AM	28-32	ATP binding cassette subfamily B member 1	Homo sapiens	114-118
17697617-16	2007	P-gp pump function and the effects of its reversal agents on leukemic cells can be rapidly and easily evaluated by using the C-AM and FCM.	calcein AM	125-129	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
17964170-1	2008	A library of chalcones with basic functionalities were screened for inhibition of P-glycoprotein (Pgp, ABCB1) by the calcein-AM accumulation assay on MDCKII/MDR1 cells.	calcein AM	117-127	PGP	Canis lupus familiaris	82-96
17964170-1	2008	A library of chalcones with basic functionalities were screened for inhibition of P-glycoprotein (Pgp, ABCB1) by the calcein-AM accumulation assay on MDCKII/MDR1 cells.	calcein AM	117-127	PGP	Canis lupus familiaris	98-101
17964170-1	2008	A library of chalcones with basic functionalities were screened for inhibition of P-glycoprotein (Pgp, ABCB1) by the calcein-AM accumulation assay on MDCKII/MDR1 cells.	calcein AM	117-127	ATP binding cassette subfamily B member 1	Canis lupus familiaris	103-108
17964170-2	2008	Three members that had ring A substituted with 5-(1-ethylpiperidin-4-yl) and 2,4-dimethoxy groups were found to increase calcein-AM accumulation to a greater extent than verapamil, a Pgp inhibitor.	calcein AM	121-131	ATP binding cassette subfamily B member 1	Homo sapiens	183-186
16960658-15	2007	Similarly with MRP1, the efflux of a fluorescent substrate calcein AM was inhibited effectively by THC thereby the accumulation of calcein was increased in MRP1-HEK 293 and not its parental pcDNA3.1-HEK 293 cells.	calcein AM	59-69	ATP binding cassette subfamily C member 1	Homo sapiens	15-19
16960658-15	2007	Similarly with MRP1, the efflux of a fluorescent substrate calcein AM was inhibited effectively by THC thereby the accumulation of calcein was increased in MRP1-HEK 293 and not its parental pcDNA3.1-HEK 293 cells.	calcein AM	59-69	ATP binding cassette subfamily C member 1	Homo sapiens	156-160
17261498-5	2007	MRP1 function was evaluated by measuring calcein acetoxymethyl ester (calcein-AM) efflux, and by verifying its inhibition by MK571, a potent MRP inhibitor.	calcein AM	41-68	ATP binding cassette subfamily C member 1	Homo sapiens	0-3
17261498-5	2007	MRP1 function was evaluated by measuring calcein acetoxymethyl ester (calcein-AM) efflux, and by verifying its inhibition by MK571, a potent MRP inhibitor.	calcein AM	70-80	ATP binding cassette subfamily C member 1	Homo sapiens	0-4
17261498-5	2007	MRP1 function was evaluated by measuring calcein acetoxymethyl ester (calcein-AM) efflux, and by verifying its inhibition by MK571, a potent MRP inhibitor.	calcein AM	70-80	ATP binding cassette subfamily C member 1	Homo sapiens	0-3
21783720-2	2006	As a result of P-gp inhibition, the increase of intracellular accumulation of a model P-gp substrate fluorescent calcein acetoxymethyl ester was measured.	calcein AM	113-140	phosphoglycolate phosphatase	Mus musculus	15-19
17050779-5	2007	Simultaneous application of any of these modulators and UIC2, followed by the removal of the modulator, results in a completely restored steady-state accumulation of various Pgp substrates (calcein-AM, daunorubicin, and 99mTc-hexakis-2-methoxybutylisonitrile), indicating near 100% inhibition of pump activity.	calcein AM	190-200	ATP binding cassette subfamily B member 1	Homo sapiens	174-177
16942742-1	2006	We report on a cost- and time-effective fluorescent dye (calcein-acetoxymethylester; calcein-AM)-based assay to screen compounds for p-glycoprotein (p-gp) interactions at the blood-brain barrier.	calcein AM	85-95	ATP binding cassette subfamily B member 1	Homo sapiens	133-147
16942742-1	2006	We report on a cost- and time-effective fluorescent dye (calcein-acetoxymethylester; calcein-AM)-based assay to screen compounds for p-glycoprotein (p-gp) interactions at the blood-brain barrier.	calcein AM	85-95	ATP binding cassette subfamily B member 1	Homo sapiens	149-153
16942742-10	2006	In summary, an improved calcein-AM assay using suspended PBCECs for screening of drug-p-gp interactions is presented .	calcein AM	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
21783720-2	2006	As a result of P-gp inhibition, the increase of intracellular accumulation of a model P-gp substrate fluorescent calcein acetoxymethyl ester was measured.	calcein AM	113-140	phosphoglycolate phosphatase	Mus musculus	86-90
16533780-5	2006	The induced Pgp transported the fluorescent substrates rhodamine 123, bisantrene, calcein-AM, BODIPY-vinblastine, and BODIPY-paclitaxel.	calcein AM	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	12-15
16859642-4	2006	The mitogenic effect of IL-17A on tracheal epithelial cells was confirmed with Calcein-AM assay.	calcein AM	79-89	interleukin 17A	Homo sapiens	24-30
16021489-7	2006	The modulatory effect of curcuminoids on MRP1 function was confirmed by the inhibition of efflux of two fluorescent substrates, calcein-AM and fluo4-AM.	calcein AM	128-138	ATP binding cassette subfamily C member 1	Homo sapiens	41-45
15531381-9	2004	The calcein-AM test in untreated cells showed that GFJ, kaempferol or naringenin inhibited Pgp activity.	calcein AM	4-14	phosphoglycolate phosphatase	Homo sapiens	91-94
15826803-5	2005	In the second part of this work, we studied the functional expression of the drug efflux pump multidrug resistance P-glycoprotein after long-term exposure to cadmium by immunoblotting with the monoclonal antibody F4 and measurement of calcein-AM+/-the P-gp inhibitor verapamil.	calcein AM	235-245	ATP binding cassette subfamily B member 1	Homo sapiens	115-129
15826803-7	2005	Calcein-AM assay showed that four weeks exposure of intestinal cells to 1, 5, and 10 microM Cd increased P-gp functional expression in proportion to the Cd concentration.	calcein AM	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
16342001-4	2005	METHODS: We characterized the inhibitory potencies of the antidepressants in two in vitro assays by using calcein-AM as Pgp substrate.	calcein AM	106-116	ATP binding cassette subfamily B member 1	Homo sapiens	120-123
16342001-8	2005	RESULTS: All of the antidepressants tested inhibit the transport of calcein-AM by Pgp in the micromolecular range.	calcein AM	68-78	ATP binding cassette subfamily B member 1	Homo sapiens	82-85
15964558-5	2005	RESULTS: Addition of fibroblasts preloaded with the fluorescent low molecular weight tracer calcein-AM to cultured myocytes indicated early dye transfer via connexin 43 functional gap junctions.	calcein AM	92-102	gap junction alpha-1 protein	Oryctolagus cuniculus	157-168
15876859-4	2005	We analysed the Pgp function by calcein acetoxymethylester (calcein-AM) uptake, a fluorescent marker substrate, before and after in vitro exposure to UFH at clinically achievable dose of 20 U/ml.	calcein AM	32-58	ATP binding cassette subfamily B member 1	Homo sapiens	16-19
15876859-4	2005	We analysed the Pgp function by calcein acetoxymethylester (calcein-AM) uptake, a fluorescent marker substrate, before and after in vitro exposure to UFH at clinically achievable dose of 20 U/ml.	calcein AM	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	16-19
15451006-7	2004	The calcein-AM efflux assay also showed that the MTT reagent inhibits the function of MDR1 in the MDCKII-MDR1 cell line.	calcein AM	4-14	ATP binding cassette subfamily B member 1	Canis lupus familiaris	86-90
15451006-7	2004	The calcein-AM efflux assay also showed that the MTT reagent inhibits the function of MDR1 in the MDCKII-MDR1 cell line.	calcein AM	4-14	ATP binding cassette subfamily B member 1	Canis lupus familiaris	105-109
15120939-2	2004	A good correlation was found between MRP1 expression and the modulatory effect of MK571 on calcein-AM uptake (P = 0.01 and probenecid effect on CFDA uptake (P = 0.02).	calcein AM	91-101	ATP binding cassette subfamily C member 1	Homo sapiens	37-41
15120939-5	2004	In conclusion, calcein-AM and CFDA uptake assays are the best choices to probe MRP1 activity and combination of two modulators may improve the efficiency of these assays.	calcein AM	15-25	ATP binding cassette subfamily C member 1	Homo sapiens	79-83